Alastair D Robertson
Overview
Explore the profile of Alastair D Robertson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
762
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aleong R, Sauer W, Robertson A, Liggett S, Bristow M
Circ Arrhythm Electrophysiol
. 2013 Jan;
6(1):137-43.
PMID: 23275278
Background: β-blockers prevent cardiac arrhythmias in patients with chronic heart failure and reduced left ventricular ejection fraction, including ventricular tachycardia/ventricular fibrillation (VT/VF). We hypothesized that prevention of ventricular arrhythmias by...
2.
Kao D, Wagner B, Robertson A, Bristow M, Lowes B
PLoS One
. 2012 Nov;
7(11):e48184.
PMID: 23144856
Background: Heart failure patients with reduced ejection fraction (HFREF) are heterogenous, and our ability to identify patients likely to respond to therapy is limited. We present a method of identifying...
3.
OConnor C, Fiuzat M, Carson P, Anand I, Plehn J, Gottlieb S, et al.
PLoS One
. 2012 Oct;
7(10):e44324.
PMID: 23071495
Background: Pharmacogenetics involves complex interactions of gene products affecting pharmacodynamics and pharmacokinetics, but there is little information on the interaction of multiple genetic modifiers of drug response. Bucindolol is a...
4.
Carson P, Fiuzat M, OConnor C, Anand I, Plehn J, Lindenfeld J, et al.
Am Heart J
. 2010 Oct;
160(4):649-54.
PMID: 20934558
Background: End point committees are routinely used to adjudicate efficacy and safety end points in clinical trials. The 2,708-patient β-Blocker Evaluation of Survival Trial (BEST) originally determined hospitalization type via...
5.
Bristow M, Murphy G, Krause-Steinrauf H, Anderson J, Carlquist J, Thaneemit-Chen S, et al.
Circ Heart Fail
. 2009 Nov;
3(1):21-8.
PMID: 19880803
Background: Adrenergic activation is an important determinant of outcomes in chronic heart failure. Adrenergic activity is regulated in part by prejunctional alpha(2C)-adrenergic receptors (ARs), which exhibit genetic variation in humans....
6.
Cleveland Jr J, Grover F, Fullerton D, Campbell D, Mitchell M, Lindenfeld J, et al.
J Thorac Cardiovasc Surg
. 2008 Sep;
136(3):774-7.
PMID: 18805284
Objective: Left ventricular assist devices are increasingly used as a bridge to transplantation. It remains unclear whether the use of pretransplant left ventricular assist devices adversely affects short-term survival after...
7.
Tate 3rd C, Robertson A, Zolty R, Shakar S, Lindenfeld J, Wolfel E, et al.
J Card Fail
. 2007 Nov;
13(9):732-7.
PMID: 17996821
Background: Quality of life (QOL) was a prespecified secondary end point in the Beta-Blocker Evaluation of Survival Trial. The Beta-Blocker Evaluation of Survival Trial used four QOL questionnaires to evaluate...
8.
Feldman A, Oren R, Abraham W, Boehmer J, Carson P, Eichhorn E, et al.
Am Heart J
. 2007 Oct;
154(5):861-9.
PMID: 17967591
Background: We determined whether low-dose oral enoximone could wean patients with ultra-advanced heart failure (UA-HF) from intravenous (i.v.) inotropic support. Chronic parenteral inotropic therapy in UA-HF is costly and requires...
9.
Quaife R, Chen M, Lynch D, Badesch D, Groves B, Wolfel E, et al.
Eur J Med Res
. 2006 May;
11(5):214-20.
PMID: 16723296
RV dysfunction in idiopathic (primary) pulmonary hypertension (IPAH) is often characterized by chamber dilation, ventricular hypertrophy, and impaired systolic function. In this study we characterize right ventricular (RV) chamber size,...
10.
Lowes B, Zolty R, Minobe W, Robertson A, Leach S, Hunter L, et al.
J Heart Lung Transplant
. 2006 May;
25(5):579-88.
PMID: 16678038
Background: In chronic heart failure due to a dilated cardiomyopathy phenotype, the molecular bases for contractile dysfunction and chamber remodeling remain largely unidentified. Methods: To investigate the feasibility of measuring...